Indications |
Oral Diabetes mellitus Adult: 200-300 mcg tid. Elderly: Initiate at lower doses. |
Contraindications |
Inflammatory bowel disease; GI obstruction or patients predisposed to it; conditions which may deteriorate as a result of increased gas formation eg, hernia; severe ketosis; diabetic coma or pre-coma; severe infection; hypersensitivity; pregnancy; lactation. Not to be used as monotherapy in IDDM. |
Warnings / Precautions |
History of laparotomy or ileus. Roemheld's syndrome, stenosis, severe hepatic or renal impairment. Child <18 yr; elderly. Monitor LFT. Treat hypoglycaemic episodes with glucose (not with sucrose). |
Adverse Reactions |
Flatulence; abdominal distension; diarrhoea; pain; skin reactions; hypoglycemia; increased LFT. Potentially Fatal: Hepatotoxicity. |
Drug Interactions |
May enhance effects of other antidiabetics including insulin. See Below for More voglibose Drug Interactions |
Mechanism of Actions |
Voligbose has general properties similar to acarbose and selectively inhibits α-glucosidase in the enteric canal, delaying the digestion and absorption of carbohydrate, thereby suppressing sharp increase in post-prandial plasma glucose. |
Administration |
Should be taken with food. (Take just before meals.) |
Storage Conditions |
Oral: Store below 30°C. |
ATC Classification |
A10BF03 - voglibose ; Belongs to the class of alpha glucosidase inhibitors. Used in the treatment of diabetes. |
Storage |
Oral: Store below 30°C. |
Available As |
|
Voglibose
Post Review about Voglibose Click here to cancel reply.
Voglibose Containing Brands
Voglibose is used in following diseases
Drug - Drug Interactions of Voglibose
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.